Edition:
Deutschland

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

13.99USD
27 May 2020
Change (% chg)

$-0.14 (-0.99%)
Prev Close
$14.13
Open
$14.00
Day's High
$14.18
Day's Low
$13.19
Volume
476,032
Avg. Vol
296,794
52-wk High
$18.58
52-wk Low
$5.51

About

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain... (more)

Buy/Sell

Sell Hold Buy
1.00 Mean rating from 1 analysts

Overall

Beta: 0.80
Market Cap(Mil.): $605.23
Shares Outstanding(Mil.): 42.83
Dividend: --
Yield (%): --

BRIEF-Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products

* MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS

BRIEF-Meridian Bioscience Partners With QuantuMDx On COVID-19 Assay

* MERIDIAN BIOSCIENCE PARTNERS WITH QUANTUMDX ON COVID-19 ASSAY Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

* MERIDIAN BIOSCIENCE INC - ANNOUNCED LAUNCH OF SEVERAL NOVEL RECOMBINANT ANTIGENS FOR DEVELOPMENT OF ANTIBODY TESTS FOR COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Announces Preliminary Q2 2020 Revenue Results

* MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

BRIEF-Meridian Bioscience Is Making Available Zero Cost Samples Of Molecular Assays For Covid-19 Detection

* MERIDIAN BIOSCIENCE - MAKING AVAILABLE ZERO COST SAMPLES OF TECHNOLOGIES TO DEVELOPERS & MANUFACTURERS OF MOLECULAR ASSAYS FOR COVID-19 DETECTION Source text for Eikon: Further company coverage:

BRIEF-Meridian Bioscience Announces FDA-Clearance For New Curian Analyzer And The Curian HPSA Assay

* MERIDIAN BIOSCIENCE ANNOUNCES FDA-CLEARANCE FOR NEW CURIAN™ ANALYZER AND THE CURIAN™ HPSA® ASSAY Source text for Eikon: Further company coverage:

Photo

Breakingviews-Epidemics are tough to turn into profit

NEW YORK (Reuters Breakingviews) - Epidemics are catastrophic for humans, and it turns out they aren’t much better for healthcare companies. The number of confirmed cases of the new coronavirus has multiplied more than 80-fold over three weeks despite measures such as travel bans, and exceeded 45,000 across 26 countries on Wednesday, according to researchers at Johns Hopkins University. Tests and treatments are in demand. Yet past events like SARS show slow research, high production costs and po

BRIEF-Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results And Reaffirms 2020 Guidance

* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER FISCAL 2020 OPERATING RESULTS AND REAFFIRMS 2020 GUIDANCE

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.02%
Rohstoffe +0.22%
Industrie +0.17%
Konjunktur abhängige Waren & Dienstleistungen +0.05%
Konjunktur unabhängige Waren & Dienstleistungen +0.09%
Finanzindustrie +0.01%
Pharma -0.01%
Technologie +0.10%
Telekommunikation -0.02%